Blitz Bureau
NEW DELHI: India has risen to 8th position globally from 123rd in the World Health Organization’s (WHO) pharmacovigilance contributions, said Union Minister for Health and Family Welfare JP Nadda on January 2.
“The Indian pharmacopoeia serves as the official book of standards for drugs in the country and is a cornerstone of India’s regulatory framework for pharmaceuticals,” he said, adding that the 10th edition reflects scientific advancements, global best practices, and India’s growing leadership in pharmaceutical manufacturing and regulation.
Nadda also highlighted the remarkable progress of the Pharmacovigilance Programme of India (PvPI) under the Indian Pharmacopoeia Commission (IPC). “India, which was ranked 123rd globally in terms of contributions to the World Health Organization’s pharmacovigilance database during 2009-2014, has now risen to 8th position worldwide in 2025,” the Health Minister said.
Nadda also highlighted that the Indian Pharmacopoeia 2026 incorporated 121 new monographs, increasing the total number of monographs to 3,340. “The coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes,” Nadda said.
Commending the IPC and the PvPI team for this significant achievement, the Health Minister Nadda stated that the strengthened pharmacovigilance ecosystem reflects India’s sustained commitment to patient safety, quality assurance, and robust regulatory vigilance.
